Navigation Links
Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm,Stent's Positive Clinical Profile

olled in its multiple clinical trials, and the growing volume of positive data and number of patients with long-term follow-up continues to reinforce the stent's favorable safety and efficacy profile. The Endeavor stent is not yet approved for use in the United States.

"With two years of follow-up in nearly 1,300 patients and the volume of positive clinical data we've seen to date, we can continue to have confidence in Endeavor's clinical performance," said Martin Leon, M.D., principal investigator of the ENDEAVOR III clinical trial and Professor of Medicine at Columbia University School of Medicine. "As the Endeavor clinical program has matured, it has provided evidence that consistent and predictable patient outcomes are being sustained through time."

Scott Ward, senior vice president at Medtronic and president of the Vascular business, added: "The Endeavor clinical program continues to generate strong cumulative evidence regarding Endeavor's overall performance. Patients have been 99.7% free from overall stent thrombosis and we've seen no late stent thrombosis in our pooled clinical trials. In addition, Endeavor has demonstrated a sustained reduction in repeat procedures of 61% compared to the Medtronic Driver(R) bare metal stent and Endeavor's death/MI rates have been trending lower than bare metal stents."

Medtronic will present additional long-term data on Endeavor in the coming months. At the EuroPCR meeting in May, Medtronic will provide updated four-year and three-year results from the ENDEAVOR I and ENDEAVOR II trials respectively, as well as new data on the next-generation Endeavor Resolute drug-eluting stent. Results from the ongoing ENDEAVOR IV trial, another large randomized trial (1,548 patients) evaluating Endeavor against the Taxus stent made by Boston Scientific, are expected to be presented in the fall.

The Endeavor stent is made of a cobalt alloy and has a unique modular architecture designed to enhance deliverability
'"/>




Page: 1 2 3

Related medicine technology :

1. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
2. Two-Year Patient Registry Results Support Safety and Efficacy of Cypher Sirolimus-Eluting Coronary Stent in Real World Uses
3. Point of Care Cardiac Analyzers Yield Rapid Cardiac Marker Results
4. Diagnosing Diabetes: Immediate HbA1c Results Improve Glycemic Control
5. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
8. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
9. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
Post Your Comments:
(Date:9/4/2015)... 4, 2015  Cumberland Pharmaceuticals (CPIX), today announced that ... at VirtualInvestorConferences.com on September 10, 2015. DATE: ... LINK: http://tinyurl.com/sep10pre This will ... invited to ask the company questions in real-time - ... association,s "virtual trade booth." If attendees are not able ...
(Date:9/4/2015)... September 4, 2015 Future Prospects ... Allergic Rhinitis drugs - new study ... Where is the market for allergic rhinitis drugs heading? ... Visiongain ,s new report shows you potential revenues and ... Our 326 page report provides 273 tables, ...
(Date:9/4/2015)... Research and Markets ... the "Veterinary Pharmaceutical Submissions in the EU ... to their offering. This practical two-day ... constituent parts of the application for marketing authorisation ... marketing authorisation is sought in the European Union, ...
Breaking Medicine Technology:Cumberland Pharmaceuticals to Webcast, Live, at VirtualInvestorConferences.com September 10 2Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Veterinary Pharmaceutical Submissions in the EU: Two day Course - London, UK - December 7-8, 2015 2
... MADISON, N.J., Aug. 12, 2011 Quest Diagnostics ... of diagnostic testing, information and services, today announced that its ... per share, payable on October 24, 2011, to shareholders of record ... About Quest Diagnostics Quest Diagnostics ...
... HeartWare International, Inc. (NASDAQ: HTWR ; ASX: ... support technologies that are revolutionizing the treatment of advanced ... scheduled to make an investor presentation at the Wedbush ... a.m. Eastern Time on Wednesday, August 17, 2011.  The ...
Cached Medicine Technology:HeartWare to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference 2
(Date:9/4/2015)... ... September 04, 2015 , ... The USC Eye Institute is ... 9 nationwide by Doximity. Faculty, residents and staff are honored to have contributed ... the quality of our ophthalmology residency program. Our faculty places a high priority on ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... Lalonde Gordon ... heat, and followed up with victory in the men’s 400 meters final, with an ... Track and Field Championships in San Jose, Costa Rica in August 2015. The 44.64 ...
(Date:9/4/2015)... ... 04, 2015 , ... FiltersFast.com, the online retail leader in ... passed up. FiltersFast.com, will ship all orders over $50.00 for free. Use ... Take advantage of this promotion now through September 8, 2015. , Filtersfast.com offers ...
(Date:9/3/2015)... Angeles, CA (PRWEB) , ... September 03, 2015 , ... ... patients as to the best practices when preparing for a bariatric procedure, some patients ... a procedure. Apart from the basic instructions typical for many types of surgery that ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... William Mattar ... William Mattar, Esq. believes this does not stop at any certain demographic or segment ... its newly produced one-minute, thirty-, fifteen- and ten-second TV commercials. , The closed captioning ...
Breaking Medicine News(10 mins):Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 2Health News:USC Ophthalmology Residency Program Ranked in Top 10 by Doximity 3Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:FiltersFast.com Wows with a Long Labor Day Weekend Shipping Offer 2Health News:Dr. Feiz and Associates Answer August's ‘Patient Submitted Question of the Month’: “How Can I Prepare for Weight Loss Surgery” 2Health News:Law Firm Focused on “Helping People” Continues to Expand on Vision 2
... Part in a Town Hall Meeting to Create Awareness ... May 5 The Candie,s Foundation announced today that ... Palin, daughter of Governor Sarah Palin of Alaska, will ... interviews to promote May 6th, the National Day to ...
... wary of finding, however , , TUESDAY, May 5 (HealthDay ... the long-sought markers that could discern which tumors are ... , The currently hot debate about the value of ... the fact that the cancer is usually so slow-growing ...
... HUNTSVILLE, Ala., May 5 Osteosarcoma is the most common ... people between the ages of 10 - 25. In "Cancer ... ), a new cancer dictionary by Dr. Edward Laughlin, learn ... amputation.An oncologist,s office can be an intimidating place to enter, ...
... 5 Viroblock SA,announces that its antiviral products boosts ... times better and a peak performance of 1000 times,against ... not,very effective against viruses, such as influenza, whose sizes ... Its patented technology (VCCD Tech) potentially inactivates all families,and ...
... Chemiluminescent Technology - , BEDFORD, Mass., May 5 ... FDA clearance 510(k) for the ACL AcuStar Hemostasis Testing ... ACL AcuStar Hemostasis Testing System, which will commence in ... the first specialty-test analyzer that offers full automation of ...
... Phone Based Survey Encourages Nurses to Give Voice to Improving ... Vigilan, the leader in software for better senior living, ... what nurses have to say about how to improve the ... living, independent living and dementia care. Vigilan is offering ...
Cached Medicine News:Health News:The Candie's Foundation Appoints Bristol Palin As Teen Ambassador 2Health News:Biomarkers May Predict Aggressiveness of Prostate Cancer 2Health News:Biomarkers May Predict Aggressiveness of Prostate Cancer 3Health News:'Cancer from A to Z': A Dictionary of Cancer-Related Terms 2Health News:Viroblock SA Reports a 99% Boost of Efficacy of Facemasks Against H5N1 2Health News:Instrumentation Laboratory Launches ACL AcuStar(TM) Hemostasis Testing System 2Health News:Instrumentation Laboratory Launches ACL AcuStar(TM) Hemostasis Testing System 3Health News:Vigilan Honors National Nurse Week in Assisted Living, Independent Living and Dementia Care 2
CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
CCR Medical conventional laryngoscopes....
CCR Medical conventional laryngoscopes....
... LMA™ Airway., ,Launched in 1988, this ... is now standard practice in general anesthesia. ... the LMA Classic™ is a safe hands ... ,The LMA Classic™ can be used for ...
Medicine Products: